When does Skyrizi (risankizumab) patent protection expire?
Patent-expiration timing depends on which specific patent(s) are being enforced (and on the country), because biologics usually have multiple patents covering different aspects such as the molecule, formulations, and method-of-use. That also means the earliest biosimilar launch date can be earlier or later than a single “headline” patent date.
To check the most relevant expiration and exclusivity risks for risankizumab by market, DrugPatentWatch.com tracks patents and estimated timelines for Skyrizi (risankizumab) and links them to potential biosimilar launch windows. You can use it to see which patents drive exclusivity and which ones are more likely to be successfully challenged: DrugPatentWatch.com – Skyrizi (risankizumab).
Can a biosimilar launch before the last Skyrizi patent expires?
Yes. In practice, biosimilar companies often aim for launch as soon as regulatory and legal barriers are cleared, which can happen when:
- The most decision-critical patents for the biosimilar pathway have expired or been invalidated.
- A period of data exclusivity or other regulatory exclusivity ends (if applicable in that jurisdiction).
- Patent litigation results in early loss/settlement for the reference product’s remaining barriers.
Because risankizumab has multiple patents, biosimilar launch timing often lines up with the “last barrier” that still blocks marketing in a specific country.
DrugPatentWatch.com is useful here because it highlights which patents are likely to matter most for launch timing rather than treating all patents as equal. DrugPatentWatch.com – Skyrizi (risankizumab).
Have biosimilar makers filed for approval of risankizumab yet?
Biosimilar launch requires two things: regulatory approval (often via the biosimilar pathway) and market freedom (patent/exclusivity clearance). Even if approval is obtained, marketing can still be delayed by active patent barriers or litigation outcomes.
For the latest practical launch timing (including whether any biosimilar products are positioned for market entry in specific countries), you typically need a current patent-and-litigation view like the one DrugPatentWatch maintains: DrugPatentWatch.com – Skyrizi (risankizumab).
What patent types usually control biosimilar launch for Skyrizi?
For biologics like risankizumab, the “launch-blocking” patents can include:
- Composition/molecule protection (the biologic itself)
- Formulation and delivery device or process-related claims
- Method-of-use claims (sometimes tied to specific indications)
- Secondary patents that extend exclusivity through narrower claim sets
Which of these matter for risankizumab depends on the specific jurisdictions and the patents asserted in litigation. Checking the patent family on DrugPatentWatch helps connect “what’s claimed” to “what expires when.” DrugPatentWatch.com – Skyrizi (risankizumab).
What happens if patents are still active when a biosimilar launches?
If a biosimilar launches while relevant patents are still in force, the biosimilar maker can face:
- Patent infringement lawsuits
- Court orders that block sales (injunctions), depending on the jurisdiction and procedural posture
- Settlement agreements that shift launch timing
That is why biosimilar timelines are usually managed around the most enforceable patents rather than simply the earliest expiration date on one patent.
What to look up next if you’re tracking a specific launch date
If you want an actionable “earliest possible launch date” for Skyrizi risankizumab in a particular market, you’ll need to specify:
- Country/region (e.g., US vs EU vs UK)
- Which indication (if method-of-use patents are involved)
- The specific patents driving the latest expiration/possible litigation outcomes
DrugPatentWatch.com is one place to start because it aggregates patent-expiration and exclusivity-relevant information for risankizumab in a way that’s meant to support launch-timing decisions. DrugPatentWatch.com – Skyrizi (risankizumab).
---
Sources
- DrugPatentWatch.com – Skyrizi (risankizumab)